ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: L03 • ACR Convergence 2024

    CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus

    Kyleigh Brimmer1, Olivia Antao1, Daniel Mayer1, Gina Sanchez1, Rebecca Francis1, Htay Htay Kyi2, Mary Salim2, Boyan Xia2, Eugenio Capitle2 and Jason Weinstein1, 1Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, 2Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
  • Abstract Number: L11 • ACR Convergence 2024

    Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification

    May Choi1, Farbod Moghaddam1, Mohammad Sajadi1, Ann E. Clarke1, Sasha Bernatsky2, Karen Costenbader3, Irene Chen4, Murray Urowitz5, John Hanly6, Caroline Gordon7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Jorge Sanchez-Guerrero10, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul Fortin15, Dafna Gladman16, Ian Bruce17, Michelle Petri18, Ellen Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Graciela Alarcón24, Ronald Van Vollenhoven25, Cynthia Aranow26, Meggan Mackay26, Guillermo Ruiz-Irastorza27, S. Sam Lim28, Murat Inanç29, Kenneth Kalunian30, Soren Jacobsen31, Christine Peschken32, Diane Kamen33, Anca Askanase34, Marvin Fritzler35 and Mina Aminghafari1, 1University of Calgary, Calgary, AB, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 4UC Berkeley and UCSF, Berkeley, CA, 5Self employed, Toronto, ON, Canada, 6Dalhousie University, Halifax, NS, Canada, 7University of Birmingham, Birmingham, United Kingdom, 8Hanyang University Medical Center, Seoul, South Korea, 9The National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, 10Krembil Research Institute, Toronto, ON, Canada, 11Cedars Sinai Medical Center, Studio City, CA, 12Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, 13University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - UniversitéLaval, Quebec, QC, Canada, 16University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 17Queen's University Belfast, Belfast, United Kingdom, 18Johns Hopkins University School of Medicine, Baltimore, MD, 19SUNY Downstate Health Sciences University, New York, NY, 20UNC physician network, Chapel Hill, NC, 21Northwestern University, Chicago, IL, 22Allegheny Health Network, Pittsburgh, PA, 23Lund University, Lund, Sweden, 24The University of Alabama at Birmingham, Oakland, CA, 25Amsterdam UMC, Amsterdam, Netherlands, 26Feinstein Institutes for Medical Research, New York, NY, 27Biobizkaia Health Research Institute, Bilbao, Spain, 28Emory University, Atlanta, GA, 29Istanbul University, Istanbul, Turkey, 30UC San Diego, La Jolla, CA, 31Rigshospitalet, Copenhagen, Denmark, 32University of Manitoba, Winnipeg, MB, Canada, 33Medical University of South Carolina, Johns Island, SC, 34Columbia University Medical Center, New York, NY, 35Mitogen Diagnostics Corp, Calgary, AB, Canada

    Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…
  • Abstract Number: L12 • ACR Convergence 2024

    A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity

    Chunli Mei1, Xin Guan1, Bin Wu2, Mengjiao Li1, Xiaojing Liu1, Xi Chen1, You Song1, Weiwei Wang1, Cheng Wang1, Huiling Mei1, Xiaoru Duan1, Lijuan Jiang1, Wenlin Qiu1, Likai Yu1, Yuhong Liu1, Xing Zhao3, Xuanfan Zhong3, Shengjie Xue3, Wuzhong Shen3, Ying Tan3, Guojian Yu3, Guiyun Tu3, Hanyang Chen3, Amy Sun3, Xiaoqiang Yan3, Anbing Huang1, Rong Du1 and Qiubai Li1, 1Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, 3ITabMed Ltd. Changchun, Shanghai, China

    Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
  • Abstract Number: L13 • ACR Convergence 2024

    Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort

    Zahi Touma1, Ian Bruce2, Richard A. Furie3, Eric Morand4, Raj Tummala5, Shelly Chandran6, Gabriel Abreu7, Jacob Knagenhjelm7, Kellyn Arnold8, Hopin Lee8, Eleanor Ralphs8, Danuta Kielar9, Aleksander Bedenkov9 and Miina Waratani9, 1Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 2Queen's University Belfast, Belfast, United Kingdom, 3Northwell Health, Manhasset, NY, 4Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 6Astrazeneca, Mississauga, ON, Canada, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8IQVIA, London, United Kingdom, 9Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: In SLE, persistent disease activity, disease flares and long-term glucocorticoid (GC) use all contribute to organ damage accrual. The effects of novel therapies on…
  • Abstract Number: L16 • ACR Convergence 2024

    Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial

    Megan Clowse1, David Isenberg2, Joan Merrill3, Thomas Dörner4, Michelle Petri5, Edward Vital6, Eric Morand7, Teri Jimenez8, Stephen Brookes9, Janine Gaiha-Rohrbach10, Christophe Martin11, Annette Nelde12 and Christian Stach13, 1Division of Rheumatology and Immunology, Duke University, Durham, NC, 2Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 5Johns Hopkins University School of Medicine, Baltimore, MD, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 8UCB, Raleigh, NC, 9Biogen, Maidenhead, United Kingdom, 10Biogen, Cambridge, MA, 11UCB, Slough, United Kingdom, 12Biogen, Baar, Switzerland, 13UCB, Monheim am Rhein, Germany

    Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
  • Abstract Number: L17 • ACR Convergence 2024

    Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial

    Yiyi Yu1, Ruina Kong1, Xia Xu1, Suxuan Liu1, Qian Chen1, Xiaofang Li2, Ming Sun2, Jianmin Yang1, Dongbao Zhao1 and Jie Gao1, 1Changhai Hospital, Shanghai, China, 2Rui Therapeutics, Nanjing, China

    Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…
  • Abstract Number: 0085 • ACR Convergence 2024

    A Novel, Potent and Selective TLR7/8 Small Molecule Inhibitor Blocks TLR7/8 Pathway in the Presence of HCQ and Demonstrates Robust Preclinical Efficacy in Lupus Models

    Ching Shang1, Angie Hammond2, Yuanjiang Yu1, Bing Xia1, Yew Ann Leong1, Emily Chung1, zhiyu Huang1, Paqui Gonzalez Traves3, Wesley Minto1, Sunish Mohanan1, Hailing Zong1, Gundula Min-oo1, Stephen Ammann4, Eda Canales5 and Natasha Crellin3, 1Gilead Sciences, Foster City, CA, 2Gilead Sciences, Inc., Seattle, WA, 3Gilead, Foster City, CA, 4Gilead Sciences, Foster City, 5Gilead Sciences, San Mateo, CA

    Background/Purpose: Toll-like receptor 7, 8 and 9 (TLR7/8/9) are endosomal nucleic acid sensors that when aberrantly activated, induce Type I interferon (IFNα), proinflammatory cytokines, immune…
  • Abstract Number: 0136 • ACR Convergence 2024

    Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network

    Federico Zazzetti1, Urbano Sbarigia2, William Giovanini3, Claire Blacketer4, Michel van Speybroeck5, Teresa A. Simon6, Guo Li3, Chetan S. Karyekar4, Reyhan Sonmez7, Manuel Ugarte-Gil8, RV, Gamboa-Cardenas9, Victor Pimentel-Quiroz10, Guillermo Pons-Estel11, Bernardo Pons-Estel12, Rosana Quintana13, Veronica Saurit14, ODIRLEI MONTICIELO15, Katiuzka Zuñiga Corrales16, Jorge Esquivel-Valerio17, Martin Rebella18, Cecilia Pisoni19, Francinne Machado Ribeiro20, Carlos Núñez-Álvarez21, Kaleb Michaud22, Patricia Katz23, Rangi Kandane-Rathnayake24, Eric Morand25, Worawit Louthrenoo26, Yi-Hsing Chen27, Jiacai Cho28, Laniyati Hamijoyo29, Shue Fen Luo30, Yeong-Jian Jan Wu30, Sandra Navarra31, Sargunan Sockalingam32, Masayoshi Harigai33, Zhuoli Zhang34, BMDB Basnayake35, Madelynn Chan36, Tsutomu Takeuchi37, Sang-Cheol Bae38, Fiona Goldblatt39, Sean O'Neill40, Kristine (Pek Ling) Ng41, Yih Jia Poh42, Nicola Tugnet43, Sunil Kumar44, Michael Tee45, Yoshiya Tanaka46 and Chak Sing. Lau47, Alberta Hoi48, Mandana Nikpour49, Mark Sapsford50, Íñigo Rúa-Figueroa50, José María Pego-Reigosa51, María Galindo-Izquierdo52, Jaime Calvo-Alén53, Antonio Fernández-Nebro54, Raúl Menor Almagro55 and Frederic Lavie56, 1Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 2Johnson & Johnson Innovative Medicine, Brussels, Belgium, 3The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, 4Janssen Research & Development, LLC, Spring House, PA, 5Janssen Pharmaceutica, Beerse, Belgium, 6Physicians Research Center, LLC, Toms River, NJ, 7EFOR-CVO Life Sciences Consultancy, Basel, Switzerland, 8Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, 9Universidad Científica del Sur, Lima, Lima, Peru, 10Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, 11Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, 12Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, 13Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 14hospital privado universitario de cordoba, Córdoba, Argentina, 15HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, 16Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 17Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 18Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, 19CEMIC, Buenos Aires, Argentina, 20Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, 21Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, 22University of Nebraska Medical Center, Omaha, NE, 23University of California San Francisco, San Francisco, CA, 24Monash University, Clayton, Victoria, Australia, 25School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 26Chiang Mai University, Chang Wat Chiang Mai, Thailand, 27Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 28National University Hospital, Kent Ridge, Singapore, 29University of Padjadjaran, Sumedang Regency and Bandung, Indonesia, 30Chang Gung Memorial Hospital, Taoyuan City, Taiwan (Republic of China), 31University of Santo Tomas, Manila, Philippines, 32University of Malaya Medical Centre, Kuala Lumpur, Malaysia, 33Tokyo Women's Medical University, Tokyo, Japan, 34Peking University First Hospital, Beijing, China, 35Teaching Hospital, Kandy, Sri Lanka, 36Tan Tock Seng Hospital, Singapore, Singapore, 37Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 38Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 39Flinders Medical Centre, Adelaide, Australia, 40Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, 41Health New Zealand Waitemata, Te Whatu Ora (North Shore Hospital), Auckland, New Zealand, 42SingHealth, Singapore, Singapore, 43Auckland District Health Board, Auckland, New Zealand, 44Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital), Auckland, New Zealand, 45University of the Philippines, Manila, Philippines, 46Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 47University of Hong Kong, Pok Fu Lam, Hong Kong, 48Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, 49The University of Sydney, Melbourne, Victoria, Australia, 50Middlemore Hospital, Auckland, New Zealand, 50Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, 6Galicia Health Service (SERGAS), Vigo, Spain, 52Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 53Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, 54Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, 55Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, 56Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need across patient populations. Real-world…
  • Abstract Number: 0185 • ACR Convergence 2024

    New and Severe Damage in a Prevalent Lupus Cohort Through the Lens of Demographic and Neighborhood Disparities

    Jonathan Katz1, Ang Yu2, Felix Elwert2, Robert Greenlee3, David Gazeley4, Ann Rosenthal5, Jenna Cormier5, Bryn Sutherland5, Shalvi Parikh6, Yiran Jiang7 and Christie Bartels8, 1University of Wisconsin Hospitals and Clinics, Madison, WI, 2University of Wisconsin-Madison, Madison, WI, 3Marshfield Clinical Research Institute, Marshfield, WI, 4Medical College of Wisconsin, Wauwatosa, WI, 5Medical College of Wisconsin, Milwaukee, WI, 6Mississippi Delta Family Medicine Residency, Greenville, MS, 7Annapolis Rheumatology, Washington, DC, 8University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Systemic Lupus Erythematosus (SLE) disproportionally affects minoritized populations.  SLE damage, assessed by SLICC/ACR Damage Index (SDI), is higher in Black than in White US…
  • Abstract Number: 0247 • ACR Convergence 2024

    Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study

    Sandra Pasoto1, Isabele Antonelli1, Ana Cristina Medeiros-Ribeiro2, Nadia Aikawa3, Leonard Kupa1, Eduardo Borba1, Luciana Seguro4, Emily Figueiredo Neves Yuki1, ANA PAULA ASSAD1, Carla Saad4, Andrea Shimabuco4, Andrea Negrini1, Julia Medeiros1, Talita Ribeiro1, Samuel Shinjo4, Percival Sampaio-Barros4, Danieli Andrade5, Fernando Souza4, Renata Miossi4, Clovis Silva6 and Eloisa Bonfa1, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, 3Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 5University of São Paulo, São Paulo, SP, Brazil, 6Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: Recently, it was demonstrated that temporarily halting mycophenolate mofetil (MMF) for 1-week post-COVID-19 vaccination in systemic lupus erythematosus (SLE) patients improved humoral response, without…
  • Abstract Number: 0437 • ACR Convergence 2024

    Describing Maternal Outcomes Among Veterans with a History of Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Deirdre Quinn1, Florentina Sileanu1, Gregory Procario1, Shannon Mitchell1 and Mehret Birru Talabi2, 1VA Pittsburgh Healthcare System, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Veterans who utilize Department of Veterans Affairs (VA) maternity benefits, nearly half (42%) of whom represent racial or ethnic minority groups, have a high…
  • Abstract Number: 0613 • ACR Convergence 2024

    Prediction of Spontaneous Abortion in Women with Systemic Lupus Erythematosus (SLE) Based on Machine Learning Model: Insights from the Egyptian College of Rheumatology (ECR)–SLE Cohort

    Nevin Hammam1, Walaa N. Ismail2, Iman I EL-Gazzar3, Osman Hammam4, Noha M Khalil5, Eman F Mohamed6, Nermeen Noshy7, Dina F El-Essawi8, Rawhya R El Shereef9, Faten Ismail9, Marwa ElKhalifa10, Hanan M Fathi11, Soha Senara11, Samar Tharwat12, Samah I Nasef13, Amany R El-Najjar14, Ahmed M Abdalla15, Ali Bakhiet16, Ahmed Elsaman17 and Tamer A Gheita3, 1Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, 2Faculty of Computers and Information, Minia University, Minia;, Minia, Egypt, 3Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, 4Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, 5Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, 6Internal Medicine Department, Rheumatology Unit, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, 7Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Ain-Shams University, Cairo, Egypt, 8Internal Medicine Department, Rheumatology Unit, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt, 9Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, 10Alexandria faculty of Medicine, Alexandria, Egypt, 11Rheumatology Department, Faculty of Medicine, Fayoum University,, Fayoum, Egypt, 12Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, 13Rheumatology Department, Faculty of Medicine, Suez-Canal University, Ismailia, Egypt, 14Rheumatology Department, Faculty of Medicine, Zagazig University, Sharkia, Egypt, 15Rheumatology Department, Faculty of Medicine, Aswan University, Aswan, Egypt, 16Higher institute of Computer Science and Information Systems, Culture & Science City, Giza, Egypt, 17Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt

    Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects women of childbearing period. SLE increases the risk of adverse pregnancy outcome including spontaneous abortion (SA), which causes emotional stress to…
  • Abstract Number: 0631 • ACR Convergence 2024

    Impact of Baseline Proteinuria Level on Long-term Outcomes in Lupus Nephritis

    Fadi Kharouf1, Qixuan Li2, Laura Patricia Whittall Garcia2, Dafna Gladman3 and Zahi Touma4, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: Proteinuria is a marker of lupus nephritis (LN) activity, damage, and response to therapy. There is still sparse evidence on the renal outcomes associated…
  • Abstract Number: 0650 • ACR Convergence 2024

    Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis

    Yevgeniya Gartshteyn1, Laura Geraldino2, Shuwei Wang3, Vivette D'Agati1 and Robert Winchester1, 1Columbia University Irving School of Medicine, New York, NY, 2Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, 3Rutgers New Jersey Medical School, Newark, NJ

    Background/Purpose:     Current classification criteria of lupus nephritis (LN) emphasize glomerular pathology, however tubular atrophy and interstitial fibrosis (TAIF) are better predictors of poor…
  • Abstract Number: 0668 • ACR Convergence 2024

    There Are No Shortcuts: Electronic Health Record-Generated Tool Does Not Reflect Medication Adherence in Patients with SLEin Bronx, NY

    Kiera Brennan1, Kai Sun2, Anitha Ramu1, Juliann Allen1, Justina Shafik1 and Noa Schwartz3, 1Albert Einstein College of Medicine, Bronx, NY, 2Duke University, Durham, NC, 3Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Nonadherence to hydroxychloroquine (HCQ) is associated with poor outcomes in SLE.1 Electronic Health Record (EHR) platforms collect data on patient medication access through dispensing…
  • 1
  • 2
  • 3
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology